FDA has approved Rasonque

What's happened

The FDA has approved daraxonrasib, sold as Rasonque, for metastatic pancreatic cancer in patients who have received prior therapy or cannot take combination chemotherapy. Clinical trial data show median survival of 13.2 months versus 6.7 months with chemotherapy. Revolution Medicines has priced a 30‑day supply at about $39,800 and is offering patient assistance.

What's behind the headline?

What this approval changes

• The FDA has delivered the first oral drug that directly targets dominant KRAS mutations in pancreatic cancer. Clinicians will now have a systemic option for patients whose metastatic disease has failed prior chemotherapy.

Who benefits and who pays

• Patients will benefit from longer median survival (13.2 months versus 6.7 months) and, on trial data, a lower rate of severe adverse events. Revolution Medicines has set a 30‑day price of about $39,800; insurers will cover most costs but out‑of‑pocket exposure will vary and co‑pay programs will determine access for many.

Clinical and research consequences

• Physicians will shift treatment pathways toward targeted therapy early for KRAS‑driven pancreatic tumours. Researchers and drugmakers will escalate trials combining daraxonrasib with other agents and testing the drug in lung, colorectal and other KRAS‑mutant cancers.

Risks and limits

• Daraxonrasib is not a cure. Side effects — skin rash, mucositis, gastrointestinal problems — will require onco‑dermatology and supportive care. Company‑funded trial data produced the main survival figures; independent real‑world studies will be required to confirm durability and broader safety.

Forecast

• The drug will rapidly enter clinical practice for eligible patients and will drive substantial revenue for Revolution Medicines. Payers and oncologists will negotiate access and monitoring protocols; within 12 months, additional trial results will define combination strategies and expanded indications.

How we got here

Researchers have long struggled to target KRAS mutations that drive most pancreatic cancers. Daraxonrasib blocks multiple KRAS subtypes by binding the mutated protein. A 500‑patient late‑stage trial reported nearly doubled median survival and fewer severe side effects compared with standard chemotherapy.

Our analysis

The Times of Israel reports that FDA officials have given expedited approval to daraxonrasib and notes Revolution Medicines will sell the pill as Rasonque at about $39,800 per month, citing company pricing and trial results showing median survival of 13.2 months versus 6.7 months for chemotherapy. France 24 and BBC Business echo the survival figures and the manufacturer’s announced price; France 24 highlights the drug’s prior expanded access program and quotes 88‑year‑old patient Barbara Andes saying the pill "allowed her to resume regular activities," while BBC Business quotes the FDA as calling the drug a "critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer." Bloomberg and the New York Times Business emphasise clinical impact and commercial potential; Bloomberg reports the final‑stage trial result and frames the drug as a major breakthrough, while the New York Times Business notes analyst expectations for high revenue and that more than 2,000 patients received the drug through the expanded access programme. The Associated Press and the Washington Post report the same primary trial outcomes and include FDA statements that the approval came more than six months ahead of the target date. Several outlets, including the Independent and AP, explain the drug’s mechanism as targeting KRAS mutations long deemed "undruggable" and describe the therapy as a molecular glue that binds multiple KRAS subtypes. On patient experience, Bloomberg and the New York Post provide individual accounts: Bloomberg quotes Jay Williams saying the drug "has been life‑changing," while the New York Post quotes Senator Ben Sasse describing severe skin effects even as he reports symptom relief. Coverage differs in emphasis: business outlets (Bloomberg, France 24) focus on stock moves, revenue forecasts and analyst projections, while health desks (AP, Times of Israel, Washington Post) prioritise survival data, side‑effect profiles and FDA timing. Several pieces note that the p

Go deeper

• How will insurers and Medicare cover Rasonque and what will typical out‑of‑pocket costs be?
• Which ongoing trials are testing daraxonrasib in other KRAS‑mutant cancers and when will results arrive?

More on these topics

• American Cancer Society - Voluntary organization

  The American Cancer Society is a nationwide voluntary health organization dedicated to eliminating cancer. Established in 1913, the society is organized into six geographical regions of both medical and lay volunteers operating in more than 250 Regional o

• California - US State

  California is a state in the Pacific Region of the United States. With 39.5 million residents across a total area of about 163,696 square miles, California is the most populous U.S. state and the third-largest by area, and is also the world's thirty-fourt

• KRAS - Protein-coding gene in the species Homo sapiens

  The KRAS gene provides instructions for making a protein called K-Ras, part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus.

• Ben Sasse - United States Senator

  Benjamin Eric Sasse is an American politician, author, professor, and academic administrator who serves as the junior United States Senator from Nebraska, a seat he was first elected to in 2014. Sasse is a member of the Republican Party.

• United States - Country in North America

  The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.

• 60 Minutes - American television program

  60 Minutes is an American television news magazine broadcast on the CBS television network. Debuting in 1968, the program was created by Don Hewitt, who chose to set it apart from other news programs by using a unique style of reporter-centered investigat

• CBS Broadcasting Inc. - Television broadcasting company

  CBS is an American commercial broadcast television and radio network that is the flagship property of the CBS Entertainment Group division of ViacomCBS.

• Nebraska - US State

  Nebraska is a state that lies both in the Great Plains and in the Midwestern United States. It is bordered by South Dakota to the north; Iowa to the east and Missouri to the southeast, both across the Missouri River; Kansas to the south; Colorado to the s

• Robert Wood Johnson Foundation - Health care company

  The Robert Wood Johnson Foundation is the United States' largest philanthropy focused solely on health; it is based in Princeton, New Jersey. The foundation's goal, through the use of grants, is "to improve the health and health care of all Americans." Th

• Howard Hughes Medical Institute - Foundation

  The Howard Hughes Medical Institute (HHMI) is an American non-profit medical research organization based in Chevy Chase, Maryland. It was founded in 1953, by Howard Hughes who was an American business magnate, investor, record-setting pilot, engineer...

• Redwood City - City in California

  Redwood City is a city on the San Francisco Peninsula in Northern California's Bay Area, approximately 27 miles south of San Francisco, and 24 miles northwest of San Jose.

• City of Hope - Wikimedia disambiguation page

  City of Hope may refer to: City of Hope (1991 film), a film taking place in fictitious Hudson City, New Jersey City of Hope (1948 film), a French drama film City of Hope National Medical Center, a cancer center in Duarte, California City of Hope (charity), the medical center's charity City of Hope, a song by Journey from Eclipse, 2011